The endoplasmic reticulum membrane complex promotes proteostasis of GABA\textsubscript{A} receptors

Highlights

- EMC3 and EMC6 positively regulate the function of endogenous GABA\textsubscript{A} receptors
- The EMC interacts with major endogenous neuroreceptors
- The EMC transmembrane domains contribute to the interaction with GABA\textsubscript{A} receptors
- Overexpressing the EMC restores the function of GABA\textsubscript{A} receptor variants
The endoplasmic reticulum membrane complex (EMC) plays a critical role in the biogenesis of tail-anchored proteins and a subset of multi-pass membrane proteins in the endoplasmic reticulum (ER). However, because of nearly exclusive expression of neurotransmitter-gated ion channels in the central nervous system (CNS), the role of the EMC in their biogenesis is not well understood. In this study, we demonstrated that the EMC positively regulates the surface trafficking and thus function of endogenous γ-aminobutyric acid type A (GABA<sub>A</sub>) receptors, the primary inhibitory ion channels in the mammalian brain. Moreover, among ten EMC subunits, EMC3 and EMC6 have the most prominent effect, and overexpression of EMC3 or EMC6 is sufficient to restore the function of epilepsy-associated GABA<sub>A</sub> receptor variants. In addition, EMC3 and EMC6 demonstrate endogenous interactions with major neuroreceptors, which depends on their transmembrane domains, suggesting a general role of the EMC in the biogenesis of neuroreceptors.

INTRODUCTION

Acquiring the correct transmembrane topology is essential for the function of membrane proteins, which consist of about 30% of the eukaryotic proteome. The endoplasmic reticulum membrane complex (EMC) plays a critical role in the insertion of membrane proteins into the lipid bilayer of the endoplasmic reticulum (ER) (Chitwood et al., 2018; Guna et al., 2018; Shurtleff et al., 2018). The EMC is ubiquitously expressed and highly conserved (Volkmar and Christianson, 2020; Wideman, 2015). Ten subunits (EMC1-10) have been identified in the EMC in mammals: EMC1, EMC3-7, and EMC10 are membrane-spanning, whereas EMC2, EMC8, and EMC9 are soluble (EMC8 and EMC9 are structurally redundant and mutually exclusive) (Figure 1A) (O’Donnell et al., 2020). Recent cryo-electron microscope (cryo-EM) structures showed the overall similar organization of the human EMC (Pleiner et al., 2020) and yeast EMC (Bai et al., 2020): both have a large ER luminal region, 12 transmembrane helices, and a smaller cytosolic region. Research has shown that EMC1-3, 5, and 6 are the core subunits because their depletion leads to co-translational degradation of other subunits, malfunction in the assembly of the full mature EMC, and loss of EMC’s overall activity in U-2 OS cells (Volkmar et al., 2019).

A growing number of EMC-dependent client membrane proteins continue to be reported (Volkmar and Christianson, 2020). The EMC was first described in yeast in a genetic screen for protein folding factors (Jonikas et al., 2009). Later, the EMC was identified in the screen of the interactome for the mammalian ER-associated degradation (ERAD) network (Christianson et al., 2011). Recently, the EMC’s important role has been recognized in inserting tail-anchored membrane proteins post-translationally and a subset of multi-pass membrane proteins co-translationally. The EMC acts as an insertase for tail-anchored proteins with moderately hydrophobic transmembrane domains (Guna et al., 2018). Subsequently, the EMC was reported to facilitate the insertion of the first transmembrane domain of certain G-protein coupled receptors (GPCRs), such as β-adrenergic receptors (Chitwood et al., 2018). Furthermore, quantitative proteomics analysis comprehensively identified EMC-dependent membrane protein clients, showing that the EMC enables the biogenesis of membrane proteins with destabilizing features, such as polar and charged residues-containing transmembrane domains (Shurtleff et al., 2018; Tian et al., 2019). The idea that the EMC could act as a more general factor to facilitate the biogenesis of membrane proteins should be further investigated because the EMC regulates the function of a variety of membrane proteins, including cystic fibrosis transmembrane conductance regulator (CFTR) in yeast, acetylcholine receptors in...
Figure 1. Effect of depleting individual EMC subunits on endogenous GABA_A receptor α1 subunit protein levels
(A) Schematics of ten EMC subunits.
(B) Cartoon Representation of heteropentameric GABA_A receptors. The most common subtype in the mammalian CNS consists of α1, β2/3, and γ2 subunits.
(C to L) Endogenous total GABA_A receptor α1 subunits protein level change on knocking down individual EMC subunits. Mouse hypothalamus GT1-7 neuronal cells were transfected with siRNAs against EMC1 to EMC10, respectively. Two distinct siRNAs targeting each of the ten EMC subunits, designated as EMCn.1 and EMCn.2 (n = 1 to 10), were used to minimize the potential off-target effects. Forty-eight hours after transfection, proteins were extracted and analyzed by western blotting. β-actin was used as the loading control. Normalized band intensity was shown below the images (n = 3). Each data point is presented as mean ± SEM *, p < 0.05; **, p < 0.01. NT: Non-targeting scrambled siRNA.

C. elegans, and rhodopsins and transient receptor potential (TRP) channels in Drosophila (Louie et al., 2012; Richard et al., 2013; Satoh et al., 2015).

We focus on proteostasis maintenance of neurotransmitter-gated ion channels (Fu et al., 2016). Because of the nearly exclusive expression of such membrane proteins in the CNS, previous screenings in yeast and mammalian cells did not identify the potential involvement of the EMC in their biogenesis (Shurtleff et al., 2018; Tian et al., 2019). Interestingly, EMC6 was shown to positively regulate the expression of acetylcholine receptors and the response to GABA in C. elegans (Richard et al., 2013). Therefore, here we evaluated the role of the EMC in the biogenesis of GABA_A receptors, the primary inhibitory ion channels in the mammalian CNS (Akerman and Cline, 2007). Functional GABA_A receptors are assembled as a pentamer in the ER from eight subunit classes: α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-3 (Sequeira et al., 2019). The most common subtype in the human brain contains two α1 subunits, two β2/3 subunits, and one γ2 subunit (Figure 1B) (Laverty et al., 2019; Zhu et al., 2018). Individual subunits must fold into their native structures in the ER and assemble with other subunits correctly on the ER membrane to form a heteropentamer (Barnes, 2001; Jacob et al., 2008; Martenson et al., 2017). Only properly assembled receptors exit the ER, traffic through the Golgi for complex glycosylation, and reach the plasma membrane for their proper function (Lorenz-Guertin and Jacob, 2018). The proteostasis network, which contains chaperones (such as BiP and calnexin), ERAD factors (such as Hrd1, Sel1L, and VCP), and trafficking factors (such as LMAN1), orchestrates the folding, assembly, degradation, and trafficking of GABA_A receptors, which is essential for their function (Di et al., 2013; Di et al., 2016; Fu et al., 2019; Wang et al., 2022b; Wang et al., 2013). Loss of function of GABA_A receptors causes a variety of neurological diseases, including epilepsy and intellectual disability (Hernandez and Macdonald, 2019). Furthermore, numerous clinical variants in a single subunit cause subunit protein misfolding and/or disrupt assembly of the pentameric complex in the ER (Fu et al., 2022). Such mutant subunits are retained in the ER and subjected to excessive ERAD, being dislocated into the cytosol and degraded by the proteasome. This leads to decreased cell surface localization of the receptor complex and imbalanced neural circuits. Because the proteostasis network orchestrates the biogenesis of GABA_A receptors, regulating the expression or function of their proteostasis network components, such as GABA_A receptor-interacting chaperones and ERAD factors, can fine-tune the functional surface expression of GABA_A receptors. Specifically, activating the pro-folding chaperones or inhibiting the ERAD factors genetically or pharmacologically has the potential to restore the surface trafficking and thus function of pathogenic GABA_A receptors, providing a therapeutic strategy to ameliorate related neurological diseases (Wang et al., 2022a; Wang et al., 2014). For example, overexpression of BiP, a pro-folding Hsp70 family chaperone in the ER, is sufficient to promote the anterograde trafficking and surface expression of pathogenic GABA_A receptors containing the A322D mutation in the α1 subunit (Di et al., 2013). Consistently, increasing the BiP protein levels pharmacologically through the application of a small molecule BiP activator called BIX leads to enhanced functional surface expression of this variant (Fu et al., 2018).

Here we aim to understand the role of each individual subunit of the EMC on the proteostasis maintenance of GABA_A receptors. We found that EMC3 and EMC6 have the most prominent effect on increasing the protein levels of endogenous GABA_A receptors. Furthermore, the interactions between the EMC and GABA_A receptors are dependent on the transmembrane domains. Overexpressing the EMC is sufficient to restore the function of certain disease-associated variants of GABA_A receptors.

RESULTS
Knocking down EMC3 and EMC6 reduces the protein levels and function of endogenous GABA_A receptors
We evaluated the effect of each of the ten individual EMC subunits on endogenous GABA_A receptor protein levels. As a starting point, we used a mouse GT1-7 hypothalamic neuronal cell line because it is...
Figure 2. Effect of EMC3 and EMC6 on the protein levels and whole-cell patch-clamping currents of endogenous GABA<sub>A</sub> receptors

(A) Mouse GT1-7 neurons were incubated with siRNA against EMC3 or EMC6 for 48 h. Proteins were extracted and analyzed by western blotting, normalized band intensity was shown below the images (n = 3), with β-actin as the loading control. 

(B) Mouse GT1-7 neurons were incubated with siRNA against EMC3 or EMC6 for 48 h. Whole-cell patch-clamping was performed on the cells with the IonFlux Mercury 16 ensemble plates at a holding potential of −60 mV. GABA (1 mM) was applied for 4 s, as indicated by the horizontal bar above the currents. The peak currents (I<sub>max</sub>) were acquired and analyzed by Fluxion Data Analyzer (n = 6 - 10). NT: Non-targeting scrambled siRNA; pA, picoampere.

(C) Confocal microscopy imaging of primary rat cortical neurons demonstrated reduced surface expression of GABA<sub>A</sub> receptors after siRNA treatment of EMC3 and EMC6 through lentivirus transduction. Lentiviruses were generated from transiently transfected HEK293T cells with the following plasmids and collected after 60 h from the media passing through a 0.45 μm filter: EMC3- or EMC6-set of four siRNA lentivectors, packaging and envelop plasmids. At day-in-vitro (DIV) 6 of the primary rat cortical neurons, lentivirus transduction was carried out at a multiplicity-of-infection (MOI) of 10. At DIV 12, neurons were stained for cell surface GABA<sub>A</sub> receptor α1 subunits (top row), β2/3 subunits (middle row), and γ2 subunits (bottom row), colored in red. DAPI staining for the nucleus was colored in blue. Scale bar = 20 μm. Quantification of the fluorescence intensity by using ImageJ was shown on the bottom after background correction from 20–30 neurons. Each data point is presented as mean ± SEM *, p < 0.05; **, p < 0.01.

Of the five core subunits of the EMC (EMC1-3, 5, and 6) that are critical for its assembly and activity, EMC1, EMC3 and EMC6 positively regulated α1 protein levels (Figures 1C, 1E and 1H), whereas the knockdown of EMC2 or EMC5 did not influence the α1 protein levels significantly (Figures 1D and 1G), suggesting that the formation of the mature EMC might not be a prerequisite for the regulation of GABA<sub>A</sub> receptor protein levels. The most substantial reduction of the total α1 protein levels was observed with the depletion of EMC3 (p < 0.01, Figure 1E) and EMC6 (p < 0.01, Figure 1H). This is noted in the figures as decreased EMC3 band intensity for EMC3.1 and EMC3.2 siRNAs-treated samples, compared to the non-targeting (NT) control, to 38 and 37% respectively (Figure 1E). Correspondingly, when α1 was detected, two decreased band intensities were observed as well, to 41 and 45% respectively (Figure 1E). We also noted significant effects on EMC6 knockdown (p < 0.01, Figure 1H) as well. This is noted as decreased EMC6 band intensity for EMC6.1 and EMC6.2 siRNAs-treated samples, compared to NT, to 70 and 58% respectively. Correspondingly, when α1 was detected, two decreased band intensities were observed as well, to 75 and 35% respectively (Figure 1H). Therefore, our results suggested that individual EMC subunit, such as EMC3 and EMC6, is sufficient to positively regulate GABA<sub>A</sub> receptor protein levels (also see below). EMC3 is the only EMC subunit that exhibits homology to Oxa1 family proteins, which are known membrane protein insertases (Volkmar and Christianson, 2020; Wideman, 2015), and EMC6 plays a critical role in regulating the biogenesis of acetylcholine receptors in C. elegans (Richard et al., 2013).

Among the five peripheral subunits of the EMC (EMC4, 7-10) that are not essential for the complex’s stability or assembly, EMC4 and EMC10 positively regulated α1 protein levels (Figures 1F and 1L), whereas the knockdown of EMC7-9 did not influence the α1 protein levels significantly (Figures 1I, 1J and 1K), again suggesting a subunit-specific contribution of the EMC. It is worth noting that all cytosolic, soluble EMC subunits (EMC2, 8-9) did not influence α1 protein levels significantly, suggesting that the transmembrane domains in other membrane-spanning EMC subunits could play a critical role in regulating GABA<sub>A</sub> receptor biogenesis in the ER membrane (also see below).

In addition, we performed experiments to detect endogenous β3 protein levels from EMC3 and EMC6 knockdown samples in GT1-7 cells to further determine their effects on other major subunits of GABA<sub>A</sub> receptors (Figure 2A). Knocking down EMC3 by using two distinct siRNAs decreased the EMC3 protein levels of the very few neuronal cells that express endogenous, functional GABA<sub>A</sub> receptors (with α1 and β3 subunits) (Hales et al., 1992). In addition, GT1-7 is a mature mouse hypothalamic gonadotropin releasing hormone cell line that responds to membrane depolarization (Hales et al., 1994), which is a defining characteristic of neurotransmitter-gated ion channels. To investigate whether there are key subunits of the EMC that play critical roles in the biogenesis of GABA<sub>A</sub> receptors, we conducted siRNA screening by using two distinct siRNAs targeting each of the ten EMC subunits to minimize the potential off-target effects. GT1-7 cells have high transfection efficiency, which also made them suitable for the siRNA screening experiments (Fu et al., 2019). To further increase knockdown efficiency, we performed two siRNA transfections at 24 and 48 h before harvesting the proteins for SDS-poly acrylamide gel electrophoresis (PAGE) and western blot analysis (Figures 1C–1L).

iScience 25, 104754, August 19, 2022
Figure 3. EMC3 and EMC6 promote anterograde trafficking of GABA<sub>A</sub> receptors

(A and B) Significant reduction of cell surface and total a1 and b2 subunits of GABA<sub>A</sub> receptors was observed when both EMC3 and EMC6 were knocked down. We carried out siRNA transfection in HEK293T cells stably expressing a1b2γ2 GABA<sub>A</sub> receptors. To test the surface expression of GABA<sub>A</sub> receptors,
Figure 3. Continued

Biotinylation experiments were performed 48 h after siRNA transfection of both EMC3 and EMC6 (A). Surface proteins were enriched through biotin–neutravidin affinity purification, and western blot analysis was applied to detect surface α1 and β2 subunits. Na+/K+ ATPase served as loading control of cell surface proteins. To test the total protein expression of GABA<sub>A</sub> receptors, cells were lysed and total proteins were collected and subjected to SDS-PAGE and western blot analysis (B). β-actin was used as the total protein loading control. Normalized band intensity was shown on the right to the blots (n = 3).

(C) The ratio of the surface/total subunits of GABA<sub>A</sub> receptors was quantified, as a measure of their surface trafficking efficiency. Data was taken from (A) and (B) for the calculation.

(D) HEK293T cells stably expressing α1β2γ2 GABA<sub>A</sub> receptors were transfected with non-targeting siRNA or siRNAs against EMC3 and EMC6. 48 h after transfection, cycloheximide (CHX) (100 μg/mL), a potent protein synthesis inhibitor, was added to cell culture media for the indicated time. Cells were then harvested, and total proteins were subjected to SDS-PAGE and western blot analysis. Quantification of the α1 band intensity was plotted against the incubation time with CHX (n = 3).

(E and F) EMC3 and EMC6 promote GABA<sub>A</sub> receptors’ trafficking from the ER to Golgi as demonstrated through endoglycosidase H (Endo H) digestion. EMC3 or EMC6 siRNA transfection was applied in HEK293T cells stably expressing α1β2γ2 GABA<sub>A</sub> receptors; 48 h after transfection, proteins were extracted, and subjected to Endo H digestion and western blot analysis. Endo H resistant bands (top two bands in lanes two and four) represent proteins that have correctly folded in the ER, trafficked to Golgi and fully modified with the N-linked complex glycans, thus becoming resistant to Endo H. On the other hand, acting upon proteins remaining in ER, Endo H may remove the high mannoside structure after the asparaginyl-N-acetyl-D-glucosamine on the α1 subunits, generating Endo H sensitive bands (bottom band in lanes two and four). The Peptide-N-Glycosidase F (PNGase F) enzyme-treated samples served as a control for unglycosylated α1 subunits (lane 5). Quantification of the ratio of Endo H resistant/total α1 band intensity, as a measure of the trafficking efficiency of α1 subunits, was shown on the right (n = 3).

(G) HEK293T cells stably expressing α1β2γ2 GABA<sub>A</sub> receptors were transfected with non-targeting siRNA or siRNAs against EMC3, EMC6, or both EMC3 and EMC6. 48 h after transfection, cells were harvested, and total proteins were subjected to SDS-PAGE and western blot analysis. Quantification of the normalized individual EMC subunit band intensity was shown on the right panels (n = 3). Each data point is presented as mean ± SEM *, p< 0.05; **, p< 0.01.

NT: Non-targeting scrambled siRNA.

to 50 and 25% compared to the non-targeting control (Figure 2A, left panel) and reduced the endogenous β3 protein levels to 55 and 30%, respectively (Figure 2A, left panel). Moreover, knocking down EMC6 by using two distinct siRNAs decreased the EMC6 protein levels to 55 and 30% compared to the non-targeting control (Figure 2A, right panel) and reduced the endogenous β3 protein levels to 50 and 25%, respectively (Figure 2A, right panel). The results from Figures 1 and 2A clearly indicated that EMC3 and EMC6 positively regulate the protein levels of the endogenous α1 and β3 subunits of GABA<sub>A</sub> receptors.

To understand their effects on the function of endogenous GABA<sub>A</sub> receptors, we carried out whole-cell patch-clamping electrophysiological recording using GT1-7 neurons after siRNA treatment of EMC3 and EMC6. The peak GABA-induced current in the non-targeting control GT1-7 neurons is 387 pA, consistently, knocking down EMC3 or EMC6 decreased the peak current (I<sub>max</sub>) to 375 and 303 pA, corresponding to 50 and 25% reduction respectively (Figure 2B). These results unambiguously demonstrated EMC3 and EMC6 as key EMC subunits to positively regulate protein expression and function of endogenous GABA<sub>A</sub> receptors.

**EMC3 and EMC6 promote anterograde trafficking of GABA<sub>A</sub> receptors**

Because GABA<sub>A</sub> receptors need to traffic to the plasma membrane for their function, we further tested the hypothesis about the necessity of the EMC with respect to surface trafficking of endogenous GABA<sub>A</sub> receptors using immunofluorescence staining. We used primary rat cortical neurons because all of the major subunits (α1, β1, β3, and γ2 subunits) of functional GABA<sub>A</sub> receptors are abundantly expressed in the plasma membrane in the cortex (Sequeira et al., 2019). EMC3 and EMC6 depletion was achieved through the lentivirus transduction of four siRNA pools (Ding and Kilpatrick, 2013). At day-in-vitro (DIV) 6 of the neurons, lentivirus transduction was carried out at a MOI of 10, that is, the ratio of lentivirus count to neuron count in each well. Immunofluorescence staining was performed at DIV 12 (Glynn and McAllister, 2006). The application of an anti-GABA<sub>A</sub> receptor subunit antibody that recognizes the extracellular epitope without a prior membrane permeabilization step using detergent enabled us to label the cell surface proteins of α1, β2/3 and γ2 subunits. Application of the Alexa Fluor Dye-conjugated secondary antibody enabled the imaging of the surface subunits using a confocal laser-scanning microscope. Clearly, depletion of EMC3 and EMC6 reduced the surface expression of α1 subunits by 37 and 41%, β2/3 subunits by 61 and 50%, and γ2 subunits by 44 and 58% in cortical neurons (Figure 2C), indicating that EMC3 and EMC6 play a critical role in positively regulating the surface trafficking of all major subunits of endogenous GABA<sub>A</sub> receptors.

In addition, we carried out surface biotinylation experiments to evaluate the effect of the EMC on exogenously expressed human α1β2γ2 GABA<sub>A</sub> receptors in HEK293T cells. HEK293T cells have been used
extensively for the functional expression of neurotransmitter-gated ion channels because HEK293T cells have low or no endogenous expression of such ion channels, and thus precise control of the subtypes can be achieved from the exogenously expressed subunits (Thomas and Smart, 2005). In addition, HEK293T cells are capable of modeling the proteostasis network that orchestrates the folding, assembly, degradation, and trafficking of neurotransmitter-gated ion channels and thus are a suitable vehicle to elucidate the biogenesis pathways of such channels (Wang et al., 2022b). After 48 h of transfection of both EMC3 and EMC6 siRNAs, surface proteins were enriched through biotin-neutravidin affinity purification (see STAR Methods), and western blot analysis was applied to detect α1 and β2 subunits (Figure 3A). Significant reduction of cell surface α1 subunits of GABA<sub>A</sub> receptors was observed when both EMC3 and EMC6 were knocked down compared to NT, to 78% or 34% when using two sets of siRNAs (Figure 3A, left panel). Similarly, cell surface β2 subunits decreased to 55% or 42% when using two sets of siRNAs (Figure 3A, right panel), when both EMC3 and EMC6 were knocked down. Because knocking down both EMC3 and EMC6 using siRNA set #2 also decreased the total protein level of α1 to 61.8% and that of β2 to 69.2% (Figure 3B), we evaluated whether the reduced surface expression of GABA<sub>A</sub> receptor subunits was a direct consequence of the lowered total receptor expression level in cells. The ratio of surface/total subunits is commonly used as a measure of their surface trafficking efficiency. Knocking down both EMC3 and EMC6 decreased such a ratio for α1 subunits to 61.5% and β2 subunits to 60.7% (Figure 3C), indicating that EMC3 and EMC6 positively regulate the surface trafficking efficiency of GABA<sub>A</sub> receptors, which could result from the post-translational effect of EMC3 and EMC6 on the folding and degradation of GABA<sub>A</sub> receptors.

We hypothesized that knocking down EMC3 and EMC6 would lead to folding and assembly defects of GABA<sub>A</sub> receptors in the ER and thus their retention in the ER and excessive degradation, causing compromised anterograde trafficking. We evaluated the effect of EMC3 and EMC6 on the degradation kinetics of GABA<sub>A</sub> receptors using cycloheximide-chase experiments. Remarkably, compared to the non-targeting control, knocking down EMC3 and EMC6 using siRNAs decreased the relative protein abundance of the α1 subunit at each time point during the 5 h chase period after the addition of cycloheximide, a potent protein synthesis inhibitor, in HEK293T cells stably expressing α1β2γ2 GABA<sub>A</sub> receptors (Figure 3D). These results indicated that depleting EMC3 and EMC6 accelerated the protein degradation of GABA<sub>A</sub> receptors. Therefore, EMC3 and EMC6 positively regulate the protein stability of GABA<sub>A</sub> receptors in cells.

Furthermore, we determined the effect of EMC3 and EMC6 on GABA<sub>A</sub> receptors’ trafficking from ER to Golgi through the endoglycosidase H (Endo H) digestion assay. The human α1 subunit of GABA<sub>A</sub> receptors has two N-linked glycosylation sites at N38 and N138. Endo H resistant bands represent glycoproteins, which have correctly folded in the ER, trafficked to the Golgi and fully modified with the N-linked complex glycans, thus becoming resistant to Endo H. On the other hand, acting on glycoproteins remaining in ER, Endo H may remove the high mannose structure after the asparaginyl-N-acetyl-D-glucosamine on the α1 subunits of GABA<sub>A</sub> receptors. We carried out EMC3 or EMC6 siRNA transfection in HEK293T cells expressing α1β2γ2 GABA<sub>A</sub> receptors; 48 h after transfection, proteins were extracted, and subjected to Endo H digestion and western blot analysis (Figures 3E and 3F). The Peptide-N-Glycosidase F (PNGase F) enzyme-treated samples served as a control for unglycosylated α1 subunits (Figures 3E and 3F, lane 5). Two endo H resistant α1 bands were observed, corresponding to singly or doubly glycosylated α1 at N38 and N138 ((Figures 3E and 3F, lane 5, lanes two and 4). Ratio of Endo H resistant α1 to total α1 represents its ER-to-Golgi trafficking efficiency. Such a ratio decreased to 0.43 with EMC3 siRNA (Figure 3E, lane 2), comparing to a ratio of 0.59 of NT (Figure 3E, lane 4). Similarly, the ratio decreased to 0.37 with EMC6 siRNA (Figure 3F, lane 2), comparing to a ratio of 0.65 of NT (Figure 3F, lane 4). Therefore, EMC3 and EMC6 have shown capability of positively regulating the stability of GABA<sub>A</sub> receptors (Figure 3D) and promoting their anterograde trafficking from the ER to the Golgi post-translationally (Figures 3E and 3F) and onward to the plasma membrane (Figures 3A and 3C).

Because EMC3 and EMC6 are the core subunits of the EMC complex, depleting them was reported to disrupt the formation of the EMC complex in U-2 OS cells (Volkmar et al., 2019). Therefore, we evaluated the effect of EMC3 and EMC6 on the stability of the entire EMC complex, which could contribute to the regulation of GABA<sub>A</sub> receptor biogenesis in HEK293T cells. Knocking down EMC3 or knocking down both EMC3 and EMC6 using siRNAs reduced the protein levels of EMC1, EMC4, EMC7, and EMC10, which are EMC subunits with transmembrane domains, whereas knocking down EMC6 reduced the protein levels of EMC4 and EMC10 (Figure 3G). The results indicated that depleting EMC3 or EMC6 reduced the protein
Figure 4. Interactions of EMC3 and EMC6 with neurotransmitter-gated ion channels

(A) Co-immunoprecipitation (Co-IP) from primary rat cortical neurons demonstrated endogenous interactions between α1 subunits of GABA$_A$ receptors and EMC3, EMC6, and a number of α1-interacting chaperones (BiP and calnexin) and...
of the proteostasis network in orchestrating GABAA receptor biogenesis (Wang et al., 2022b), we observed endogenous interactions within the pentameric receptors. Furthermore, because of the important role of Grp94 and VCP in facilitating the degradation of GABAA receptors (Di et al., 2013, 2016; Han et al., 2022), we continued to understand the interactions between EMC3/EMC6 and other major neuroreceptors, including GABAA receptors, N-methyl-D-aspartate receptors (NMDARs, including NR1, NR2A and NR2B subunits) and nicotinic acetylcholine receptors (nAChRs) (Wang et al., 2022b).

ERAD factors (Grp94 and VCP). Neurons were plated onto 10-cm dishes at a density of one million per dish. At DIV 12, proteins were extracted for Co-IP. IgG was used as a negative control during the immunoprecipitation. n = 3.

(B) Co-IP from primary rat cortical neurons demonstrated endogenous interactions between EMC3/EMC6 and a number of ion channels, including N-methyl-D-aspartate receptors (NMDARs, including NR1, NR2A and NR2B subunits) and nicotinic acetylcholine receptors (nAChRs) (Wang et al., 2022b). The cDNAs of FLAG-tagged EMC3, either in the wild type (WT) form or carrying appropriate mutations of R31A or R180A, were transiently transfected in HEK293T cells stably expressing FLAG-tagged EMC3 or EMC6. Endogenous interactions were confirmed between EMC3/EMC6 and selected ion channels. n = 3.

(C) Co-IP from mouse cortical homogenates, which were prepared from C57BL/6J mice between 8 and 10 weeks of age, demonstrated endogenous interactions between EMC3/EMC6 and selected ion channels. n = 3.

(D) Schematic of the primary sequence of EMC3 and EMC6. R31 and R180 in EMC3 and N22 and D27 in EMC6 were reported to influence the biogenesis of EMC-dependent client proteins.

(E) Mutation of R31A or R180A in EMC3 significantly reduced the interaction of EMC3 with GABA$_{\alpha_1}$ subunits. The cDNAs of FLAG-tagged EMC3, either in the wild type (WT) form or carrying appropriate mutations of R31A or R180A, were transiently transfected in HEK293T cells stably expressing a1b2y2 GABA$_{\alpha_1}$ receptors. 48 h after transfection, proteins were extracted from cell lysates and incubated with anti-FLAG M2 magnetic beads. The immuno-purified eluents were separated through SDS-PAGE gel, and western blot analysis was performed to detect a1 subunits and FLAG. Quantification of the band intensity of a1 over FLAG after immunoprecipitation was shown on the right (n = 3).

(F) Mutation of D27A or N22A in EMC6 significantly reduced the interaction of EMC6 with GABA$_{\alpha_1}$ subunits. Transfection of cDNAs was applied similarly as in E, however with co-application of FLAG-tagged EMC3 and EMC6 variants in HEK293T cells stably expressing a1b2y2 GABA$_{\alpha_1}$ receptors. Co-IP and visualization of protein bands were carried out the same way as in E as well. Quantification of the band intensity of a1 over FLAG-tagged EMC6 after immunoprecipitation was shown on the right (n = 3).

(G) Significant increase of the interaction of SEC61a and a1 subunits of GABA$_{\alpha_1}$ receptors was observed when both EMC3 and EMC6 were knocked down. We carried out siRNA transfection in HEK293T cells stably expressing a1b2y2 GABA$_{\alpha_1}$ receptors; 48 h after transfection, proteins were extracted from cell lysates and incubated with anti-a1 antibody. The immuno-purified eluents were separated through SDS-PAGE gel, and western blot analysis was performed to detect SEC61a and a1 subunits. Quantification of the band intensity of SEC61a over a1 after immunoprecipitation was shown on the right (n = 3). Each data point is presented as mean ± SEM *, p< 0.05; **, p< 0.01. NT: Non-targeting scrambled siRNA; IP: immunoprecipitation; EV: empty vector; WT: wild type.

levels of several other EMC subunits with transmembrane domains, leading to the disruption of the EMC complex. Markedly, EMC3 had a more dramatic effect than EMC6 on the protein levels of other EMC subunits. Therefore, individual EMC subunits could have different levels of capacity to stabilize the EMC, which in turn could contribute to their differentiating influence on the protein levels of GABA$_{\alpha_1}$ receptors. However, it is still possible that EMC3 and EMC6 could have their distinct functional role on the folding and trafficking of GABA$_{\alpha_1}$ receptors independent of the formation of the EMC complex.

Co-immunoprecipitation demonstrated endogenous interactions between EMC3/EMC6 and a number of major neuroreceptors, including GABA$_{\alpha_1}$ receptors, N-methyl-D-aspartate receptors (NMDARs), and nicotinic acetylcholine receptors (nAChRs)

To facilitate the biogenesis of its client membrane proteins, the EMC is expected to interact with them. Therefore, we continued to understand the interactions between EMC3/6 and GABA$_{\alpha_1}$ receptors. Rat cortical neurons at DIV 12 were harvested to perform co-immunoprecipitation. Endogenous interactions were confirmed between a1 subunits and EMC3/EMC6 (Figure 4A). In addition, as expected, pulling down a1 subunits led to the detection of b2/3 and y2 subunits of GABA$_{\alpha_1}$ receptors, indicating the endogenous interactions within the pentameric receptors. Furthermore, because of the important role of the proteostasis network in orchestrating GABA$_{\alpha_1}$ receptor biogenesis (Wang et al., 2022b), we observed a1-interacting chaperones, including BiP and calnexin, and ERAD factors, including Grp94 and VCP (Figure 4A). Previously, we demonstrated the role of BiP and calnexin in assisting the folding and the role of Grp94 and VCP in facilitating the degradation of GABA$_{\alpha_1}$ receptors (Di et al., 2013, 2016; Han et al., 2015a, 2015b).

Furthermore, we evaluated whether the EMC has a more general role in interacting with other major endogenous neurotransmitter-gated ion channels, including nAChRs and NMDA receptors. Both GABA$_{\alpha_1}$ receptors and nAChRs belong to the Cys-loop superfamily neuroreceptors, sharing a pentameric scaffold (Fu et al., 2016), whereas NMDA receptors are tetramers, consisting of two NR1 subunits and two NR2 subunits (NR2A or NR2B, or both) (Hansen et al., 2021). Dysfunction of these receptors leads to neurological, cognitive and psychiatric brain diseases (Shen et al., 2016a; Steinlein, 2012; Wanamaker et al., 2003). Co-immunoprecipitation experiments demonstrated that pulling down EMC3 or EMC6 resulted in the detection of NR1, NR2A, and NR2B subunits of NMDA receptors as well as a7 subunits of nAChRs in
primary cortical neurons (Figure 4B). In addition, mouse cortical homogenates from C57BL/6J mice between 8 and 10 weeks of age, which have developed mature nervous systems, were used to detect the endogenous interactions between EMC3/EMC6 and selected neuroreceptors in physiologically relevant conditions. Consistently, co-immunoprecipitation assay showed that EMC3 and EMC6 interacted with α1 and β2/3 subunits of GABA_a receptors, NR1 subunit of NMDA receptors, and α7 subunit of nAChRs in cortical homogenates (Figure 4C). These experiments successfully demonstrated the interactions between the EMC and a number of major neuroreceptors in both early and mature stages of development, suggesting that the EMC not only assists folding of GABA_a receptors but also potentially plays critical roles for the biogenesis of other multi-pass transmembrane receptors in the CNS.

Mutating key transmembrane residues of EMC3 and EMC6 significantly impairs their capability of interacting with GABA_a receptors

Next, we determined whether the interactions between EMC3/6 and GABA_a receptors are through their transmembrane domains. For EMC3, previous literature has shown the importance of positive residues at Arg31 (R31) in transmembrane helix 1 (TM1) and Arg180 (R180) in transmembrane helix 3 (TM3) (Figure 4D), and the absence of such positive residues destabilize post- and co-translational insertion of EMC-dependent substrates, such as squalene synthase and opioid kappa receptor 1 (Pleiner et al., 2020). For that reason, we hypothesized that a neutral residue at such positions would likewise destabilize the interaction between EMC3 and GABA_a receptors. FLAG-tagged WT EMC3 or EMC3 carrying appropriate mutations of R31A or R180A were transiently transfected in HEK293T cells stably expressing α1β2γ2 GABA_a receptors. The immuno-purified eluents were separated through SDS-PAGE, and western blot analysis was performed to detect α1 subunits and FLAG. As demonstrated by normalized α1 intensity over FLAG, comparing to WT EMC3, significant decrease of the interaction of mutant EMC3 and α1 subunits was observed, to an extent of 0.48 with R31A, or 0.40 with R180A, respectively (Figure 4E). Therefore, the result indicated that a neutral residue replacement at R31 in TM1 and R180 in TM3 impairs EMC3’s capability to interact with GABA_a receptors.

Moreover, EMC6 residues in the hydrophilic vestibule are thought to be necessary for the insertion of its substrates (Figure 4D) (Pleiner et al., 2020). Asp27 (D27) in TM1 has been shown with such possibility, and is conserved across several species such as Homo sapiens, M musculus, and Saccharomyces cerevisiae (Pleiner et al., 2020). In addition, Asn22 (N22) has been identified in TM1 of EMC6 within hydrogen bonding distance of the main chain of EMC5, which contributes to the stabilization of TM1 of EMC6 in the lipid bilayer. Therefore similarly, FLAG-tagged EMC5 and appropriate EMC6 variants were transfected in HEK293T cells stably expressing α1β2γ2 GABA_a receptors. Co-expression of EMC5 with EMC6 was necessary because EMC5 is required to stably insert EMC6’s TM1 (Pleiner et al., 2020). Comparing to WT EMC6, its variants led to significant decrease of its interaction with α1 subunits, to an extent of 0.72 with D27A, or 0.55 with N22A, respectively (Figure 4F). The result indicated that D27 and N22 in TM1 play critical roles for EMC6’s interaction with GABA_a receptors. Taken together, we showed that the interactions between EMC3/6 and GABA_a receptors are dependent on the key charged/polar residues in the TM domains of the EMC, consistent with the role of the EMC as an insertase for multi-pass transmembrane proteins.

Furthermore, because the SEC61 translocon is known to play a crucial role in the insertion of secretory and membrane polypeptides into the ER co-translationally (Skach, 2009) and the EMC coordinates with SEC61 for the insertion of transmembrane proteins (Chitwood et al., 2018; O’Keefe et al., 2021), we investigated the potential orchestration of SEC61 and EMC on the GABA_a receptor biogenesis. We carried out siRNA transfection of both EMC3 and EMC6 in HEK293T cells stably expressing α1β2γ2 GABA_a receptors. Co-immunoprecipitation experiments showed that significant increase of the interaction of SEC61α and α1 subunits of GABA_a receptors was observed when both EMC3 and EMC6 were knocked down, as demonstrated by normalized SEC61α over α1 intensity comparing to NT, to a remarkable extent of 5.3-fold (Figure 4G). Therefore, the result suggested that on depletion of EMC3 and EMC6, GABA_a receptors would be routed to the SEC61 translocon for the insertion into the lipid bilayer.

Overexpression of EMC3 and EMC5/6 restores functional surface expression of disease-associated variants (DAVs) of GABA_a receptors

Based on the above-mentioned results, increasing the EMC expression has the promise to enhance forward trafficking and thus surface expression of GABA_a receptors, and ultimately their function as neurotransmitter-gated ion channels. To investigate this hypothesis, we evaluated the role of key EMC
subunits in epilepsy-associated GABAA receptor variants, which are known to cause subunit misfolding and reduced surface expression, including α1(D219N), α1(G251D), and α1(P260L) (Fu et al., 2022; Han et al., 2015b; Kodera et al., 2016). We carried out cDNA transfection of EMC3 or co-application of EMC5 and EMC6 in HEK293T cells expressing the variants. With EMC3 overexpression, significantly increased surface expression of α1 subunits of GABAAR was observed in HEK293T cells stably expressing α1(D219N)β2y2 (Figure 5A), α1(G251D)β2y2 (Figure 5B) and α1(P260L)β2y2 (Figure 5C), to 260%, 285%, and 148% respectively. Similarly, with co-application of EMC5 and EMC6, surface α1 subunits increased to 380%, 235%, and 285% respectively in α1(D219N)β2y2 (Figure 5A), α1(G251D)β2y2 (Figure 5B) and α1(P260L)β2y2 (Figure 5C). Moreover, cycloheximide-chase experiments demonstrated that overexpressing EMC5 and EMC6 substantially slowed down the degradation of α1(G251D) variant in HEK293T cells stably expressing α1(G251D)β2y2 GABAAR receptors (Figure 5D). These results indicated that co-application of EMC5 and EMC6 stabilized the α1(G251D) variant to promote their trafficking to the plasma membrane.

To further evaluate the EMC’s effects on the function of these variants, whole-cell patch-clamping was performed on cells 48 h after transfection using the Fluxion automated patch clamping instrument (see STAR Methods). Increased GABA-induced currents were recorded, as shown in α1(D219N)β2y2 (Figure 5E), α1(G251D)β2y2 (Figure 5F) and α1(P260L)β2y2 (Figure 5G). With EMC3 overexpression, the peak current (I∞) increased from 239 pA to 355 pA and from 185 pA to 285 pA respectively in α1(G251D)β2y2 (Figure 5F) and α1(P260L)β2y2 (Figure 5G); no significant change was observed in α1(D219N)β2y2 (Figure 5E), potentially because of its lesion being in the ER lumen, whereas the EMC acts preferably on the transmembrane domains (Chitwood and Hegde, 2019). Moreover, with co-application of EMC5 and EMC6, I∞ increased from 270 pA to 550 pA, 239 pA to 325 pA, and 185 pA to 370 pA respectively in α1(D219N)β2y2 (Figure 5E), α1(G251D)β2y2 (Figure 5F) and α1(P260L)β2y2 (Figure 5G). We observed a modest increase in the peak current compared to the substantial increase in the surface expression of α1 subunit variants because the peak current is also determined by multiple electrophysiological parameters (Sallard et al., 2021). The macroscopic current amplitude at a given time point is the product of the number of open channels and their single channel conductance. The open states of GABAAR receptors are also influenced by several kinetic parameters, such as activation, desensitization, and deactivation time scales. In addition, GABAAR receptors on the cell surface could have binary forms (α1 and β2 subunits) in addition to triheteromeric forms (α1, β2 and γ2 subunits); these two forms have different single channel conductance. Since the cell surface α1 subunits could have different opening probability and single channel conductance, their quantity is not strictly proportional to the observed macroscopic peak current amplitude. Such a discrepancy was also reported in GABAAR receptors containing p1 variants (Hannan and Smart, 2018). Nonetheless, these results indicated that overexpression of EMC3 or EMC5/6 is sufficient to enhance the function of DAVs of GABAAR receptors.

DISCUSSION

In this study, we systematically examined the effects of all 10 individual subunits of the EMC complex on regulating endogenous GABAAR receptor protein expression. Significant reduction of the protein levels of GABAAR receptor subunits, including α1, β2/β3, and γ2 subunits, and GABA-induced currents were observed from knocking down EMC3 and EMC6 in neurons (Figures 1 and 2). Knocking down EMC3 or EMC6 reduced the protein levels of several other EMC subunits with transmembrane domains in HEK293T cells (Figure 3G),...
consistent with the report that depleting core EMC subunits disrupts the EMC complex in U-2 OS cells (Volkmar et al., 2019). It appears that depleting EMC3 downregulated more EMC subunits than depleting EMC6. Therefore, on one hand, individual EMC subunits could stabilize the EMC complex to a different extent, causing their differentiating influence on the protein levels of GABAA receptors. On the other hand, because overexpressing EMC3 or EMC5/6 was sufficient to increase the functional surface expression of several GABAA receptor variants (Figure 5), it is also possible that EMC3 and EMC6 could execute their functional role on GABAA receptor folding and trafficking independent of the formation of the EMC complex, which would suggest a subunit-specific contribution of the EMC in regulating the biogenesis of a multi-pass transmembrane protein. Intriguingly, consistent results have been reported, showing that the EMC3-EMC6 fusion protein is sufficient to insert the mitochondrial protein Cox2 and nuclear encoded inner membrane proteins (Günogr et al., 2022), suggesting that certain EMC subunits are capable of carrying out the membrane insertase function. EMC3 is homologous to known membrane protein insertases Oxa1 family proteins (Volkmar and Christianson, 2020; Wideman, 2015), and depletion of EMC3 results in ER stress and activates the unfolded protein response (Huang et al., 2021; Tang et al., 2017). Moreover, EMC3 was reported to coordinate the assembly of lipids and proteins required for surfactant synthesis (Tang et al., 2017), maintain differentiation and function of intestinal exocrine secretory lineages (Huang et al., 2021), and play a critical role in mammalian retinal development (Cao et al., 2021; Zhu et al., 2020). In parallel, in addition to its role in regulating the biogenesis of acetylcholine receptors in C. elegans (Richard et al., 2013), EMC6 was reported to regulate the autophagosome formation, and knocking down EMC6 impaired autophagy (Li et al., 2013). Moreover, the important role of EMC6 as a therapeutic target for cancer and pancreatic inflammatory diseases has been increasingly recognized (Shen et al., 2016b; Tan et al., 2020; Wang et al., 2017; Xiao et al., 2021). Nonetheless, the potential subunit-specific contribution of the EMC to the membrane protein quality control merits further investigation.

Our data support a working model about the role of the EMC in GABAA biogenesis in the ER (Figure 6). The EMC, including EMC3 and EMC6, interacts with the nascent subunits of GABAA receptors through the transmembrane domains. Mechanistic studies revealed that R31 in TM1 and R180 in TM3 of EMC3, and D27 and N22 in TM1 of EMC6 are essential residues for EMC’s interaction with GABA_A receptors (Figures 4D–4F), consistent with the structural work of the EMC (Pleiner et al., 2020). Therefore, the EMC facilitates the insertion of the transmembrane domains of GABAA receptor subunits into the lipid bilayer. Subsequently, molecular chaperones, such as BiP and calnexin, promote the productive folding of GABAA receptors (Di et al., 2013; Han et al., 2015b). After the proper assembly of the pentameric receptors on the ER membrane, GABAA receptors engage the trafficking factors, such as LMAN1 (Fu et al., 2019), en route to the Golgi and onward to the plasma membrane. Consistently, we demonstrated that EMC3 and EMC6 promote the anterograde trafficking of GABAA receptors (Figure 3). Here, we focused on GABAA receptor subtypes in the synaptic sites containing the α1 subunit. Given the substantial diversity of GABAA receptor subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-3), numerous subtypes of GABAA receptors containing the combination of subunits can form either in the synaptic sites to trigger fast, transient phasic inhibition or in the extrasynaptic sites to generate persistent tonic inhibition (Farrant and Nusser, 2005). The α1-α3
subunits are primarily synaptic, whereas α4, α6, and δ subunits are predominantly extrasynaptic (Lorenz-Guertin and Jacob, 2018). Tonic receptors have high affinity to GABA to respond to its “spill over” with low conductance. Since synaptic receptors and extrasynaptic receptors have different subunit composition and functional characteristics, it would be of great interest to determine whether the EMC complex plays similar roles in regulating the biogenesis of phasic and tonic GABA_A receptors in future studies. Furthermore, since EMC3 and EMC6 interact with major endogenous neurotransmitter-gated ion channels in primary neurons, including Cys-loop receptors and glutamate receptors (Figures 4A–4C), the EMC could have a general role in the CNS. It would be of great interest to identify the endogenous interactomes of the EMC subunits, such as EMC3 and EMC6, as a way to determine their client membrane proteins in the CNS in the future.

Loss of function of inhibitory GABA_A receptors is one of the primary causes of genetic epilepsy. Recent advance in genetics has identified over 150 epilepsy-associated variants in the major subunits (α1, β2, β3, and γ2) of GABA_A receptors (Absalom et al., 2022; Fu et al., 2022; Hernandez and Macdonald, 2019; Hirose, 2014). Despite the development of numerous anti-seizure drugs, about one-third epilepsy patients are resistant to current drug treatment (Rincon et al., 2021), and many of them have genetic causes (Smolarz et al., 2021). Therefore, there is an urgent need to develop new therapeutic strategy to treat epilepsy, especially drug-resistant epilepsy. Because one major disease-causing mechanism for loss of function of GABA_A receptors is their reduced trafficking to the plasma membrane, one promising approach is to adapt the proteostasis network to restore their surface trafficking and thus function (Di et al., 2013, 2021; Fu et al., 2018; Han et al., 2015a, 2015b). Recently, we showed that pharmacological activation of the ATF6 arm of the unfolded protein response using small molecules AA147 and AA263 restored the functional surface expression of misfolding-prone GABA_A variants containing α1(D219N), γ2(R82Q), or γ2(R177G) by increasing the protein levels of pro-folding chaperones, such as BiP, and the interactions between these chaperones and GABA_A variants; importantly, ATF6 activators are more selective for folding defective variants compared to wild type receptors (Wang et al., 2022a). Furthermore, such a selectivity was also reported when other small molecule proteostasis regulators, such as verapamil, dinoprost, and dihydroergocristine, were applied to rescue misfolding-prone GABA_A variants (Di et al., 2021; Han et al., 2015b), indicating that adapting the proteostasis network has the promise to achieve selectivity for disease-associated variants. Here, we demonstrated that overexpression of EMC3 and EMC5/6 enhances the functional surface expression of a number of folding-deficient GABA_A receptor variants (Figure 5). Because EMC3 and EMC5/6 interact with both inhibitory GABA_A receptors and excitatory NMDARs and nAChRs (Figures 4A–4C), the EMC complex has the potential to regulate the biogenesis of a number of neuroreceptors that regulate excitation-inhibition balance. Therefore, in order to evaluate the suitability of the EMC as the therapeutic target to rescue pathogenic GABA_A receptors, future research is needed to determine whether activating the EMC is capable of achieving selectivity to correct the function of misfolding-prone GABA_A receptor variants over wild type receptors.

Limitations of the study

The current study did not elucidate how the EMC coordinates with other proteostasis network components to orchestrate the biogenesis of GABA_A receptors in the ER. In addition, the potential general role of the EMC in regulating the protein quality control of neurotransmitter-gated ion channels in the CNS needs to be further investigated.

STAR Methods

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Cell lines
- METHOD DETAILS
  - Reagents
  - Antibodies
ACKNOWLEDGMENTS

This work was supported by the National Institutes of Health (R01NS105789 and R01NS117176 to TM, R01NS117176-02S1 to AW) and Flora Stone Mather Center for Women Research and Professional Development Grant (to AW).

AUTHOR CONTRIBUTIONS

Conceptualization, A.W., Y.W., and T.M.; Data curation: A.W. and Y.W.; Formal analysis: A.W., Y.W., and T.M.; Funding acquisition: A.W. and T.M.; Supervision: Y.W. and T.M.; Writing – original draft: A.W., Y.W., and T.M.; Writing – review & editing: A.W., Y.W., and T.M.

DECLARATION OF INTERESTS

The authors declare no competing interests.

INCLUSION AND DIVERSITY

One or more authors of this paper self-identifies as an underrepresented ethnic minority in science. One or more authors of this paper received support from a program designed to increase minority representation in science.

Received: March 9, 2022

Revised: June 30, 2022

Accepted: July 7, 2022

Published: August 19, 2022

REFERENCES

Absalom, N.L., Liao, V.W.Y., Johannesen, K.M.H., Gardella, E., Jacobs, J., Lesca, G., Gokce-Samar, Z., Arzimanoglou, A., Zeidler, S., Striano, P., et al. (2022). Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies. Nat. Commun. 13, 1822. https://doi.org/10.1038/s41467-022-29280-x.

Akerman, C.J., and Cline, H.T. (2007). Refining the roles of GABAergic signaling during neural circuit formation. Trends Neurosci. 30, 382–389. https://doi.org/10.1016/j.tins.2007.06.002.

Bai, L., You, Q., Feng, X., Kovach, A., and Li, H. (2020). Structure of the ER membrane complex, a transmembrane-domain insertase. Nature 584, 475–478.

Barnes, E.M. (2001). Assembly and intracellular trafficking of GABA(A) receptors. Int. Rev. Neurobiol. 48, 1–29.

Cao, X., An, J., Cao, Y., Lu, J., Wang, J., Ding, Y., Lin, X., and Zhou, X. (2021). EMC3 is essential for retinal organization and neurogenesis during mouse retinal development. Invest. Ophthalmol. Vis. Sci. 62, 31. https://doi.org/10.1167/iovs.21-29280.

Chitwood, P.J., and Hegde, R.S. (2019). The role of EMC during membrane protein biogenesis. Trends Cell Biol. 29, 371–384.

Chitwood, P.J., Juszkiewicz, S., Guna, A., Shao, S., and Hegde, R.S. (2018). EMC is required to initiate accurate membrane protein topogenesis. Cell 175, 1507–1519.

Christianson, J.C., Olzmann, J.A., Shaler, T.A., Sowa, M.E., Bennett, E.J., Richter, C.M., Tyler, R.E., Greenblatt, E.J., Harper, J.W., and Kopito, R.R. (2011). Defining human ERAD networks through an integrative mapping strategy. Nat. Cell Biol. 14, 93–105. https://doi.org/10.1038/ncb2383.

Di, X.J., Han, D.Y., Wang, Y.J., Chance, M.R., and Mu, T.W. (2013). SAHA enhances Proteostasis of epilepsy-associated GABA(A) receptors. Chem. Biol. 20, 1456–1468. https://doi.org/10.1016/j.chembiol.2013.09.020.

Di, X.J., Wang, Y.J., Cotter, E., Wang, M., Whittsette, A.L., Han, D.Y., Sangwung, P., Brown, R., Lynch, J.W., Keramidas, A., and Mu, T.W. (2021). Proteostasis regulators restore function of epilepsy-associated GABA(A) receptors. Cell Chem. Biol. 28, 46–59.

Di, X.J., Wang, Y.J., Han, D.Y., Fu, Y.L., Duerfeldt, A.S., Blagg, B.S., and Mu, T.W. (2016). Grp94 protein delivers g-aminobutyric acid type A (GABAA) receptors to Hrd1 protein-mediated endoplasmic reticulum-associated degradation. J. Biol. Chem. 291, 9526–9539.

Ding, B., and Kilpatrick, D.L. (2013). Lentiviral vector production, titration, and transduction of primary neurons. Methods Mol. Biol. 1018, 119–131. https://doi.org/10.1007/978-1-62703-444-9_12.

Farrant, M., and Nusser, Z. (2005). Variations on an inhibitory theme: phasic and tonic activation of
GABA\(_\text{A}\) receptors. Nat. Rev. Neurosci. 6, 215–229. https://doi.org/10.1038/nrn1625.

Fu, X., Wang, Y.J., Kang, J.Q., and Mu, T.W. (2022). GABA\(_\text{A}\) Receptor Variants in Epilepsy [Brisbane (AU) Exon Publications]. https://doi.org/10.36255/exon-publications-epilepsy-gaba-receptor.

Fu, Y.L., Han, D.Y., Wang, Y.J., Di, X.J., Yu, H.B., and Mu, T.W. (2018). Remodeling the endoplasmic reticulum proteostasis network restores proteostasis of pathogenic GABA\(_\text{A}\) receptors. PLoS One 13, e0207948. https://doi.org/10.1371/journal.pone.0207948.

Fu, Y.L., Wang, Y.J., and Mu, T.W. (2016). Proteostasis maintenance of cys-loop receptors. Adv. Protein Chem. Struct. Biol. 103, 1–23.

Fu, Y.L., Zhang, B., and Mu, T.W. (2019). LMAN1 (ERGIC-53) promotes trafficking of neuroreceptors. Biochem. Biophys. Res. Commun. 511, 356–362.

Glynn, M.W., and McCullister, A.K. (2006). Immunocytochemistry and quantification of protein colocalization in cultured neurons. Nat. Protoc. 1, 1287–1290. https://doi.org/10.1038/nprot.2006.220.

Guna, A., Volkmar, N., Christianson, J.C., and Hegde, R.S. (2018). The ER membrane protein complex is a transmembrane domain insertase. Science 359, 470–473. https://doi.org/10.1126/science.aao3099.

Güngör, B., Flohr, T., Garg, S.G., and Herrmann, J.M. (2022). The ER membrane complex (EMC) can functionally replace the Oxa1 insertase in mitochondrial protein folding. iScience 25, 331–343.

Jonikas, M.C., Collins, S.R., Denic, V., Oh, E., Quan, E.M., Schmid, V., Weibezahn, J., Schwappach, B., Walter, P., Weisson, J.S., and Schuldiner, M. (2009). Comprehensive characterization of genes required for protein folding in the endoplasmic reticulum. Science 323, 1693–1697.

Kodera, H., Ohba, C., Kato, M., Maeda, T., Araki, K., Tajima, D., Matsu, S., Hino-Fukuyo, N., Kohashi, K., Ishiyama, A., et al. (2016). De novo GABA\(_\text{A}\)R1 mutations in Ohthara and West syndromes. Epilepsia 57, 566–573. https://doi.org/10.1111/epe.13344.

Laverty, D., Desai, R., Ucharaiši, T., Masulis, S., Stoe, W.J., Malinasauskas, T., Zivanav, J., Pardon, E., Steyaert, J., Miller, K.W., and Aricescu, A.R. (2019). Cryo-EM structure of the human x1b3y2 GABA\(_\text{A}\) receptor in a lipid bilayer. Nature 565, 516–520. https://doi.org/10.1038/s41586-018-0333-4.

Li, Y., Zhao, Y., Hu, J., Xiao, J., Qu, L., Wang, Z., Ma, D., and Chen, Y. (2013). A novel ER-localized transmembrane protein, EMC6, interacts with RAB5A and regulates cell autophagy. Autophagy 9, 150–163. https://doi.org/10.1080/14770310.2012.689721.

Lorenz-Guentert, J.M., and Jacob, T.C. (2018). GABA\(_\text{A}\) type receptor trafficking and the architecture of synaptic inhibition. Dev. Neurobiol. 78, 238–270. https://doi.org/10.1002/dneu.22536.

Louie, J.R., Guo, J., Rodgers, J.W., White, R., Shah, N., Fagant, S., Kim, P., Livston, M., Dolinski, K., McKinney, B.A., et al. (2012). A yeast phenotypic model for the gene interaction network modulating CFTOR-S658 protein biogenesis. Genome Med. 4, 103. https://doi.org/10.1186/gm404.

Mortensen, J.S., Yamasaki, T., Chaudhury, N.H., Allerbeth, D., and Tomita, S. (2017). Assembly rules for GABA\(_\text{A}\) receptor complexes in the brain. Elife 6, e30826. https://doi.org/10.7554/eLife.27443.

O’Donnell, J.P., Phillips, B.P., Yagita, Y., Juszkiwetz, S., Wagner, A., Malinverni, D., Keenan, R.J., Miller, E.A., and Hegde, R.S. (2020). The architecture of EMC reveals a path for membrane protein insertion. Elife 9, e57887. https://doi.org/10.7554/eLife.57887.

O’Keeffe, S., Zong, G., Duah, K.B., Andrews, L.E., Shi, W.G., and High, S. (2021). An alternative pathway for membrane protein biosynthesis at the endoplasmic reticulum. Commun. Biol. 4, 021–02363.

Plenér, T., Tomaleri, G.P., Januszky, I., Inglis, A.J., Haru, M., and Voorhees, R.M. (2020). Structural basis for membrane insertion by the human ER membrane protein complex. Science 369, 433–436.

Richard, M., Baulin, T., Robert, V.J., Richmond, J.E., and Bessereau, J.L. (2013). Biosynthesis of ionotropic acetylcholine receptors requires the evolutionarily conserved ER membrane complex. Proc. Natl. Acad. Sci. USA 110, E1055–E1063.

Rincon, N., Barr, D., and Velez-Ruiz, N. (2021). Neuronomodulation in drug resistant epilepsy. Aging Dis. 12, 1070–1080. https://doi.org/10.14336/ad.2021.0211.

Sallard, E., Letoumeur, D., and Legendre, P. (2021). Electrophysiology of ionotropic GABA receptors. Cell. Mol. Life Sci. 78, 5341–5370. https://doi.org/10.1007/s00018-021-03846-2.

Satoh, T., Ohba, A., Liu, Z., Inagaki, T., and Satoh, A.K. (2015). dPob/EMC is essential for biosynthesis of rhodopsin and other multi-pass membrane proteins in Drosophila photoreceptors. Elife 4, e06306. https://doi.org/10.7554/eLife.06306.

Sequeira, A., Shen, K., Gottlieb, A., and Limon, A. (2019). Human brain transcriptome analysis finds region- and subject-specific expression signatures of GABA\(_\text{A}\)R subunits. Commun. Biol. 2, 153. https://doi.org/10.1038/s42003-019-0413-7.

Shen, L., Cui, W.Y., Chen, R.Z., and Wang, H. (2016a). Differential modulation of GABA\(_\text{A}\) and NMDA receptors by α7-nicotinic receptor desensitization in cultured rat hippocampal neurons. Acta Pharmacol. Sin. 37, 312–321.

Shen, X., Kan, S., Hu, J., Li, M., Lu, G., Zhang, M., Zhao, S., Hou, Y., Chen, Y., and Bai, Y. (2016b). EMC6/TMEM93 suppresses glioblastoma proliferation by modulating autophagy. Cell Death Dis. 7, e2043. https://doi.org/10.1038/cddis.2015.408.

Shurtleff, M.J., Izhak, D.N., Hussmann, J.A., Schirle Oakdale, N.T., Costa, E.A., Jonikas, M.C., Weissman, J.S., Schwappach, B., Walter, P., Schuldiner, M., and Schuldiner, S. (2022). The ER membrane protein complex is a transmembrane domain insertase. Cell. Mol. Life Sci. 79, 325–337. https://doi.org/10.1007/s00018-021-03846-2.

Skach, W.R. (2009). Cellular mechanisms of membrane protein folding. Nat. Struct. Mol. Biol. 16, 606–612.

Smolarz, B., Makowska, M., and Romanowicz, H. (2021). Pharmacogenetics of drug-resistant epilepsy (review of literature). Int. J. Mol. Sci. 22, https://doi.org/10.3390/ijms22111696.
Steinlein, O.K. (2012). Ion channel mutations in neuronal diseases: a genetics perspective. Chem. Rev. 112, 6334–6352. https://doi.org/10.1021/cr300044d.

Tan, J.H., Cao, R.C., Zhou, L., Zhou, Z.T., Chen, H.J., Xu, J., Chen, X.M., Jin, Y.C., Lin, J.Y., Qi, Z.C., et al. (2020). EMC6 regulates acinar apoptosis via APAF1 in acute and chronic pancreatitis. Cell Death Dis. 11, 966. https://doi.org/10.1038/s41419-020-03177-3.

Tang, X., Snowball, J.M., Xu, Y., Na, C.L., Weaver, T.E., Clair, G., Kyle, J.E., Zink, E.M., Ansong, C., Wei, W., et al. (2017). EMC3 coordinates surfactant protein and lipid homeostasis required for respiration. J. Clin. Invest. 127, 4314–4325.

Thomas, P., and Smart, T.G. (2005). HEK293 cell line: a vehicle for the expression of recombinant proteins. J. Pharmacol. Toxicol. Methods 51, 187–200. https://doi.org/10.1016/j.vascn.2004.08.014.

Tian, S., Wu, Q., Zhou, B., Choi, M.Y., Ding, B., Yang, W., and Dong, M. (2019). Proteomic analysis identifies membrane proteins dependent on the ER membrane protein complex. Cell Rep. 28, 2517–2526.e5. https://doi.org/10.1016/j.celrep.2019.08.006.

Vollmar, N., and Christianson, J.C. (2020). Squaring the EMC - how promoting membrane protein biogenesis impacts cellular functions and organismal homeostasis. J. Cell Sci. 133, 243519.

Wang, Y.J., Di, X.J., and Mu, T.W. (2014). Using pharmacological chaperones to restore proteostasis. Pharmacol. Res. 83, 3–9.

Wang, Y.J., Han, D.Y., Tabib, T., Yates, J.R., 3rd, and Mu, T.W. (2013). Identification of GABA(C) receptor protein homeostasis network components from three tandem mass spectrometry proteomics approaches. J. Proteome Res. 12, 5570–5586. https://doi.org/10.1021/pr400535z.

Wideman, J.G. (2015). The ubiquitous and ancient ER membrane protein complex (EMC): tether or not? F1000Res 4, 624.

Xiao, W., Cao, R.C., Yang, W.J., Tan, J.H., Liu, R.Q., Kan, H.P., Zhou, L., Zhang, N., Chen, Z.Y., Chen, X.M., et al. (2021). Roles and clinical significances of ATF6, EMC6, and APAF1 in prognosis of pancreatic cancer. Front. Genet. 12, 730847. https://doi.org/10.3389/fgene.2021.730847.

Zhu, S., Noviello, C.M., Teng, J., Walsh, R.M., Jr., Kim, J.J., and Hibbs, R.E. (2018). Structure of a human synaptic GABAA receptor. Nature 559, 67–72.

Zhu, X., Qi, X., Yang, Y., Tian, W., Liu, W., Jiang, Z., Li, S., and Zhu, X. (2020). Loss of the ER membrane protein complex subunit Emc3 leads to retinal bipolar cell degeneration in aged mice. PLoS One 15, e0238435. https://doi.org/10.1371/journal.pone.0238435.
## STAR METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Mouse monoclonal anti-GABA<sub>a</sub>R α1 (clone BD24) | Millipore | MAB339; RRID:AB_2108828 |
| Mouse monoclonal anti-GABA<sub>a</sub>R β2/3 (clone 62-3G1) | Millipore | 05-474; RRID:AB_309747 |
| Rabbit monoclonal anti-GABA<sub>a</sub>R α1 | Synaptic systems | 224203; RRID:AB_2232180 |
| Rabbit polyclonal anti-GABA<sub>a</sub>R γ2 | Synaptic systems | 224003; RRID:AB_2263066 |
| Rabbit polyclonal anti-GABA<sub>a</sub>R α1 | R&D systems | PPS022, RRID:AB_2294487 |
| Fluorescent anti-β-actin antibody Rhodamine | Biorad | 12004163; RRID:AB_2861334 |
| Mouse monoclonal anti-β-actin | Sigma Aldrich | A1978; RRID:AB_476692 |
| Mouse monoclonal anti-FLAG (clone M2) | Sigma Aldrich | F1804; RRID:AB_262044 |
| Rabbit polyclonal anti-calnexin | Enzo life sciences | ADI-SPA-B60-F; RRID:AB_11178981 |
| Rat monoclonal anti-Grp94 (clone 9G10) | Enzo life sciences | ADI-SPA-850-F; RRID:AB_11179746 |
| Rabbit polyclonal anti-VCP | Abgent | AP6920b; RRID:AB_1968401 |
| Rabbit polyclonal anti-SEC61α | Proteintech | 24935-1-AP; RRID:AB_2879807 |
| Rabbit polyclonal anti-Grp78 | Abcam | ab21685; RRID:AB_2119834 |
| Rabbit monoclonal anti-Na+/K+-ATPase | Abcam | ab76020; RRID:AB_1310695 |
| Rabbit polyclonal anti-EMC1 | Abcepta | AP10226b; RRID:AB_10817224 |
| Rabbit polyclonal anti-EMC2 | Proteintech | 25443-1-AP; RRID:AB_2750836 |
| Rabbit polyclonal anti-EMC3 | Abcepta | AP5782a; RRID:AB_10816577 |
| Rabbit polyclonal anti-EMC4 | Abcepta | AP14717a; RRID:AB_11137185 |
| Rabbit polyclonal anti-EMC5 | Pierce | PAS-56905; RRID:AB_2844014 |
| Rabbit polyclonal anti-EMC6 | Pierce | PAS-10719; RRID:AB_2878385 |
| Rabbit polyclonal anti-EMC7 | Pierce | PAS-52688; RRID:AB_2641011 |
| Mouse monoclonal anti-EMC8 | Proteintech | 66547-1-IG; RRID:AB_2881909 |
| Rabbit polyclonal anti-EMC9 | Abcepta | AP5632b; RRID:AB_10821215 |
| Rabbit polyclonal anti-EMC10 | Abcepta | APS188a; RRID:AB_10663060 |
| Rabbit monoclonal anti-NR1 antibody | Abcam | ab109182; RRID:AB_10862307 |
| Rabbit monoclonal anti-NR2A | Abcam | ab124913; RRID:AB_10975154 |
| Rabbit monoclonal anti-NR2B | Abcam | Ab183942; RRID:AB_2889878 |
| Rabbit polyclonal anti-nAChR α7 | Abcam | ab182442 |
| Goat anti-Mouse IgG (H + L) Secondary Antibody, HRP | Invitrogen | 31430; RRID:AB_228307 |
| Goat anti-Rabbit IgG (H + L) Secondary Antibody, HRP | Invitrogen | 31460; RRID:AB_228341 |
| Goat anti-Rat IgG (H + L) Secondary Antibody, HRP | Invitrogen | 31470; RRID:AB_228356 |
| Alexa Fluor 594-conjugated goat-anti-rabbit secondary antibody | Invitrogen | A11037; RRID:AB_2534095 |
| Alexa Fluor 594-conjugated goat-anti-mouse secondary antibody | Invitrogen | A11032; RRID:AB_2534091 |

(Continued on next page)
## REAGENT or RESOURCE SOURCE IDENTIFIER

### Bacterial and virus strains

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| MAX Efficiency Dh5α competent cells | Invitrogen | 18258012 |
| psPAX2 | Addgene | 12260 |
| pMD2.G | Addgene | 12259 |
| scrambled siRNA lentivector | Abmgood | LV015-G |
| EMC3-set of four siRNA lentivectors (rat) | Abmgood | 468690960395 |
| EMC6-set of four siRNA lentivectors (rat) | Abmgood | 471140960395 |

### Biological samples

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Sprague Dawley rat E18 brain cortex tissue | BrainBits | SDECX |

### Chemicals, peptides, and recombinant proteins

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Dulbecco’s Modified Eagle Medium | Fisher Scientific | 10-013-CV |
| Dulbecco’s Phosphate Buffered Saline | Fisher Scientific | SH3002803 |
| Fetal Bovine Serum (FBS), heat-inactivated | Fisher Scientific | SH3039603Hi |
| HEK293 SFM II | Invitrogen | 11686-029 |
| Penicillin-Streptomycin | Fisher Scientific | SV30010 |
| Trypsin protease | Fisher Scientific | SH3023601 |
| Accutase | Sigma Aldrich | A6964 |
| HEPES | Invitrogen | 15630-080 |
| Neurobasal Medium | Invitrogen | 21103049 |
| B-27 supplement (50X) | Invitrogen | 17504044 |
| GlutaMAX Supplement | Invitrogen | 35050061 |
| DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) | Invitrogen | D1306 |
| Opti-MEM Reduced Serum Medium | Invitrogen | 31985070 |
| TansIT-2020 Transfection Reagent | Mirus Bio | MIR S400 |
| HiPerfect Transfection Reagent | Qiagen | 301707 |
| poly-D-lysine | Sigma Aldrich | P6407 |
| Poly-L-lysine | Fisher Scientific | ICN15017710 |
| Laminin | Sigma Aldrich | L2020 |
| Ara-C hydrochloride | Sigma Aldrich | C6645 |
| Lent-X concentrator | Takara Bio | 631231 |
| G418 sulfate | Enzo Life Sciences | ALX-380-013-G005 |
| DMSO | Fisher Scientific | BP231100 |
| γ-Aminobutyric acid | Sigma Aldrich | A2129 |
| Cycloheximide | Enzo Life Sciences | ALX-380-269-G001 |
| Protein A/G plus-agarose beads | Santa Cruz | SC-2003 |
| Normal mouse IgG | Santa Cruz | SC-2025 |
| anti-FLAG M2 magnetic beads | Sigma Aldrich | M8823 |
| Sulfo-NHS-SS-Biotin | APEXBio | A8005 |
| N-ethylmaleimide (NEM) | ThermoFisher Pierce | PI23030 |
| NeutrAvidin agarose resin | ThermoFisher Pierce | PI29200 |
| Complete mini EDTA-free protease inhibitor cocktail | Roche | 4693159001 |
| n-Dodecyl-B-D-maltoside (DDM) | GoldBio | DDM5 |
| Endo Hs enzyme | NEB | P0703L |

(Continued on next page)
Continued

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Peptide-N-Glycosidase F (PNGase F) enzyme | NEB | P0704L |
| 40% acrylamide/Bis Solution 29:1 | Biorad | 1610146 |
| 2x Laemmli sample buffer | Biorad | 1610737 |
| 4x Laemmli sample buffer | Biorad | 1610747 |
| Super- Signal West Pico PLUS Chemiluminescent Substrate | ThermoFisher Pierce | 34578 |
| Super- Signal West Femto Maximum Sensitivity Substrate | ThermoFisher Pierce | 34096 |

Critical commercial assays

- MicroBCA protein assay | ThermoFisher Pierce | 23235 |
- QuikChange II site-directed mutagenesis Kit | Agilent Genomics | 200523 |
- qPCR lentivirus titration kit | Abmgood | LV900 |

Experimental models: Cell lines

- HEK293T (donor sex: female) | ATCC | CRL-3216; RRID:CVCL_0063 |
- GT1-7 Mouse Hypothalamic Neuronal Cell Line | Millipore | SCC116; RRID:CVCL_0281 |

Experimental models: Organisms/strains

- C57BL/6J mice | The Jackson Laboratory | RRID:IMSR_JAX:000664 |

siRNA

| siRNA | SOURCE | IDENTIFIER |
|-------|--------|------------|
| siRNA non-targeting control | Dharmacon | D-001810-01-20 |
| EMC1.1 | Dharmacon | J-059370-09-0005 |
| EMC1.2 | Dharmacon | J-059370-10-0005 |
| EMC2.1 | Dharmacon | J-049743-09-0005 |
| EMC2.2 | Dharmacon | J-049743-10-0005 |
| EMC3.1 | Dharmacon | J-056059-09-0005 |
| EMC3.2 | Dharmacon | J-056059-11-0005 |
| EMC4.1 | Dharmacon | J-046351-09-0005 |
| EMC4.2 | Dharmacon | J-046351-10-0005 |
| EMC5.1 | Dharmacon | J-041149-09-0005 |
| EMC5.2 | Dharmacon | J-041149-11-0005 |
| EMC6.1 | Dharmacon | J-047425-10-0005 |
| EMC7.1 | Dharmacon | J-051219-09-0005 |
| EMC7.2 | Dharmacon | J-051219-11-0005 |
| EMC8.1 | Dharmacon | J-046488-09-0005 |
| EMC8.2 | Dharmacon | J-046488-10-0005 |
| EMC9.1 | Dharmacon | J-046998-09-0005 |
| EMC9.2 | Dharmacon | J-046998-10-0005 |
| EMC10.1 | Dharmacon | J-041588-11-0005 |
| EMC10.2 | Dharmacon | J-041588-12-0005 |

Recombinant DNA

| Plasmid: human GABAAR-α1 (pCMV6) | OriGene Technologies | RC205390 |
| Plasmid: human GABAAR-β2 (pCMV6) | OriGene Technologies | RC216424 |
| Plasmid: human GABAAR-γ2 (pCMV6) | OriGene Technologies | RC209260 |
| Plasmid: pCMV6 Entry vector | OriGene Technologies | PS100001 |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ting-Wei Mu (tingwei.mu@case.edu).

Materials availability
All plasmids generated in this study will be made available on request but we may require a payment and/or a completed Materials Transfer Agreement.

Data and code availability
● All data reported in this paper will be shared by the lead contact on request.
● This paper does not report original code.
● Any additional information required to reanalyze the data reported in this paper is available from the lead contact on request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell lines
HEK293T cells (#CRL-3216, donor sex: female) were obtained from ATCC. GT1-7 cells (catalog #: SCC116) were obtained from Millipore. Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with 10% heat-inactivated fetal bovine serum (FBS) and 1% Penicillin-Streptomycin at 37°C in 5% CO₂.

METHOD DETAILS

Reagents
The pCMV6 plasmids containing human GABAₐ receptor α1 (Uniprot no. P14687-1), β2 (isoform 2, Uniprot no. P47870-1), γ2 (isoform 2, Uniprot no. P18507-2) subunits, and pCMV6 Entry Vector plasmid (pCMV6-EV) were obtained from OriGene. The human FLAG-tagged EMC3 plasmid was purchased from GenScript (catalog #: OHu03021D). The human FLAG-tagged EMC5 plasmid (catalog #: RC207046) and FLAG-tagged EMC6 plasmid (catalog #: RC215548) were obtained from OriGene. The mutations GABRA1-D219N, GABRA1-G251D, GABRA1-P260L, EMC3-R31A, EMC3-R180A, EMC6-D27A, and EMC6-N22A were constructed using QuikChange II site-directed mutagenesis Kit (Agilent Genomics, catalog #: 200523). All cDNA sequences were confirmed by DNA sequencing.

The following small interfering RNA (siRNA) duplexes were obtained from Dharmacon: EMC1.1 (J-059370-09-0005), EMC1.2 (J-059370-10-0005), EMC2.1 (J-049743-09-0005), EMC2.2 (J-049743-10-0005), EMC3.1 (J-056059-09-0005), EMC3.2 (J-056059-11-0005), EMC4.1 (J-046351-09-0005), EMC4.2 (J-046351-10-0005),
EMC5.1 (J-041149-09-0005), EMC5.2 (J-041149-11-0005), EMC6.1 (J-047425-10-0005), EMC6.2 (J-047425-12-0005), EMC7.1 (J-051219-09-0005), EMC7.2 (J-051219-11-0005), EMC8.1 (J-046488-09-0005), EMC8.2 (J-046488-10-0005), EMC9.1 (J-046998-09-0005), EMC9.2 (J-046998-10-0005), EMC10.1 (J-041588-11-0005), EMC10.2 (J-041588-12-0005), human EMC3.1 (J-010715-17-0005), human EMC3.2 (J-010715-18-0005), human EMC6.1 (J-014711-19-0005), human EMC6.2 (J-014711-20-0005), and Non-Targeting (NT) siRNA (D-001810-01-20), which was used as a negative control. The designation of EMCn.1 and EMCn.2 (n = 1 to 10) indicates two distinct siRNA sequences against each EMC subunit.

**Antibodies**

The rabbit polyclonal EMC1 antibody (catalog #: AP10226b), rabbit polyclonal EMC3 antibody (catalog #: AP5782a), rabbit polyclonal EMC4 antibody (catalog #: AP14717a), rabbit polyclonal EMC9 antibody (catalog #: AP5632b), and rabbit polyclonal EMC10 antibody (catalog #: AP5188a) were from Abcepta. The rabbit polyclonal EMC2 antibody (catalog #: 25443-1-AP) and mouse monoclonal EMC8 antibody (catalog #: 66547-1-IG) were obtained from Proteintech. The rabbit polyclonal EMC5 antibody (catalog #: PA5-56905), rabbit polyclonal EMC6 antibody (catalog #: PAS-107119), and rabbit polyclonal EMC7 antibody (catalog #: PAS-52688) were from Pierce.

The mouse monoclonal anti-GABAA α1 subunit antibody (clone BD24) (catalog #: MAB339) and mouse monoclonal anti-GABAβ2/β3 antibody (catalog #: 05-474) were obtained from Millipore. The rabbit monoclonal anti-GABAβ2/β3 antibody (catalog #: 224203) and rabbit polyclonal anti-GABAβ2 γ2 antibody (catalog #: 224003) were obtained from Synaptic systems. The rabbit polyclonal anti-GABAβ2 α1 antibody came from R&D systems (catalog #: PS5022). The mouse monoclonal anti-β-actin antibody (catalog #: A1978) and mouse monoclonal FLAG antibody (catalog #: F1804) came from Sigma Aldrich. The fluorescent anti-β-actin antibody Rhodamine came from Biorad (catalog #: 12004163). The rabbit polyclonal anti-calnexin (catalog #: ADI-SPA-860-F) and rat polyclonal anti-Grp94 (catalog #: ADI-SPA-850-F) antibodies were purchased from Enzo Life Sciences. The rabbit polyclonal anti-VCP (catalog #: AP6920b) were purchased from Abgent. The rabbit polyclonal anti-SEC61α antibody was obtained from Proteintech (catalog #: 24935-1-AP). The rabbit polyclonal anti-Grp78 antibody (catalog #: ab21685), rabbit monoclonal anti-NR1 antibody (catalog #: ab109182), rabbit monoclonal anti-NR2A antibody (catalog #: ab124913), rabbit monoclonal anti-NR2B antibody (catalog #: ab183942), and rabbit polyclonal anti-nAChR α7 antibody (catalog #: ab182442), and sodium potassium ATPase antibody (catalog #: ab76020) were purchased from Abcam.

The secondary antibodies used from Invitrogen included: HRP-conjugated goat-anti-rabbit (catalog #: A11037) and goat-anti-mouse (catalog #: A11032).

**Cell culture and transfection**

HEK293T cells (catalog #: CRL-3216) were obtained from ATCC, and GT1-7 cells (catalog #: SCC116) were obtained from Millipore. Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Fisher, catalog #: SH3024301) with 10% heat-inactivated fetal bovine serum (ThermoFisher, catalog #: SH3039603H) and 1% Penicillin-Streptomycin (HyClone, catalog #: sv30010) at 37°C in 5% CO2. Cells were grown in 6-well plates or 10-cm dishes and allowed to reach 70% confluency before transient transfection using TransIT-2020 (Mirus, catalog #: MIR 5400), or siRNA treatment (50 nM) using the HiPerfect Transfection Reagent (Qiagen, catalog #: 301707) according to the manufacturer’s instruction. A second siRNA transfection was performed 24 h after the first siRNA treatment to increase knockdown efficiency. Forty-eight hours after transfection, cells were harvested for further analysis.

Stable cell lines for α1β2γ2, α1(D219N)b2γ2, α1(G251D)b2γ2, and α1(P260L)b2γ2 were generated using the G-418 selection method. Briefly, cells were transfected with α1:b2γ2 (1:1:1), α1(D219N)b2γ2 (1:1:1), α1(G251D)b2γ2 (1:1:1) or α1(P260L)b2γ2 (1:1:1) plasmids, selected in DMEM supplemented with 0.8 mg/mL G418 (Enzo Life Sciences) for 10 days, and then maintained in DMEM supplemented with 0.4 mg/mL G418. G-418 resistant cells were used for experiments.

**Western blot analysis**

To harvest total proteins, cells were washed with Dulbecco’s phosphate-buffered saline (DPBS) (Fisher, catalog #: SH3002803). Trypsin (0.05%) (Fisher, catalog #: SH30236 01) was added to lift the cells, and DMEM was added to harvest cells from the dish and pipette into a centrifuge tube. Cells were spun down for 3 min
at 1000 rpm and then DMEM was removed while avoiding the pellet. Cell pellets were washed with DPBS and centrifuged again at 1000 rpm for 3 min. The DPBS was removed, and pellets were stored on ice during transport to a −80°C freezer. Cells were lysed with lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, and 2 mM n-Dodecyl-B-D-maltoside (DDM) (GoldBio, catalog #: DDMS)) supplemented with complete protease inhibitor cocktail (Roche). Cells were vortexed for 30 s followed by ultrasonication for 30 s for three times. Then they were centrifuged at 15,000 × g, 4°C for 10 min to obtain the supernatant as total proteins.

The protein concentration was measured according to Thermo Fisher MicroBCA kit protocol. Cell lysates were loaded with Laemmli sample buffer (Biorad, catalog #: 1610747) with β-mercaptoethanol (1:10 v/v) and separated through SDS-PAGE gel.

Before proceeding to western blot, gels were made ranging from 8% to 20% resolving gel depending on the size of the protein with 4% stacking gel on top. To run SDS-PAGE gel electrophoresis, gels were place in a holding voltage cassette and submerged in the running buffer, which contained the following: 25 mM Tris (Sigma, catalog #: T1503), 192 mM Glycine (Sigma, catalog: # 8898), and 0.1% (w/v) of sodium dodecyl sulfate (SDS, Biorad, catalog #: 1610302). Protein ladder was added (Biorad, catalog #: 1610395). Gels were run at 10 min at 100 volts until the samples passed the stacking gel and were uniformly aligned. For the remaining time of 45 min to 1 h, gels were run at 150 V. After running samples to sufficient molecular weight, gels were transfected at 100 V for 1 h to a nitrocellulose membrane. The transfer buffer contained the following: 25 mM Tris (Sigma, catalog #: T1503), 192 mM Glycine (Sigma, catalog: # 8898), 20% (v/v) of methanol (Fisher Chemical, catalog #: A452-4). After the transfer, membranes were washed briefly in TBS-T, which contained the following: 20 mM Tris (Sigma, catalog #: T1503), 150 mM NaCl (Sigma, catalog #: S7653), pH 7.6, and 0.1% (v/v) Tween20 (Sigma, catalog #: P7949-500mL). They were further incubated in 5% non-fat milk powder (Nestle Carnation, catalog #: 43875) in TBS-T for 30 min to 2 h. Following the blocking step, the membranes were incubated in 1% milk with the primary antibody added starting at 1:1000 dilution and adjusted accordingly on subsequent runs. The following day, the membrane was washed 3 times with TBS-T for 10 min each and incubated with their secondary antibody (1:10,000) for 1 h. This was followed by 3 more washed with TBS-T. Afterward gels were exposed with Pico PLUS (catalog #: 34578) or Femto (catalog #: 34096) SuperSignal West chemiluminescent substrates from Thermo Scientific for three minutes. After using different exposure times to get optimal images, results were analyzed to quantify band intensity using ImageJ software from the NIH.

Co-immunoprecipitation (Co-IP)

Cell lysates (500 µg) were pre-cleared with 30 µl of protein A/G plus-agarose beads (Santa Cruz, catalog #: sc-2003) and 1 µg of normal mouse IgG antibody (Santa Cruz, catalog #: sc-2025) for 1 h at 4°C to remove non-specific binding proteins. The pre-cleared cell lysates were incubated with 2.0 µg of mouse anti-x1 antibody for 1 h at 4°C, and then with 30 µl of protein A/G plus agarose beads overnight at 4°C. For FLAG-tagged proteins, the pre-cleared cell lysates were incubated with 30 µl of anti-FLAG M2 magnetic beads (Sigma, catalog #: M8823-5 mL) overnight at 4°C. IgG serves as negative control. The beads were collected by centrifugation at 8000 × g for 30 s or using a magnet separator (Promega), and washed three times with lysis buffer. The complex was eluted by incubation with 30 µl of Laemmli sample loading buffer in the presence of β-mercaptoethanol. The immuno-purified eluents were separated through SDS-PAGE gel, and western blot analysis was performed.

Lentivirus transduction in rat cortical neurons

Lentivirus were generated from transiently transfected HEK293T cells and collected after 60 h from the media. Briefly, HEK293T cells were grown in 10-cm dishes and allowed to reach ~70% confluency before transient transfection using TransIT-2020 (Mirus), according to the manufacturer’s instruction. The following plasmid (6 µg) was added to 10-cm dishes: EMC3-set of four siRNA lentivectors (rat, Abmgood, catalog #: 468690960395), or EMC6-set of four siRNA lentivectors (rat, Abmgood, catalog #: 471140960395), or scrambled siRNA lentivector (Abmgood, catalog #: LV015-G) as the control. Additionally, to form the lentivirus, the following packaging and envelop plasmids were added to all of the 10-cm dishes as well: psPAX2 (6 µg) and pMD2.G (0.75 µg). psPAX2 (Addgene plasmid #: 12260; http://n2t.net/addgene:12260; RRID: Addgene_12260) and pMD2.G (Addgene plasmid: 12259; RRID:Addgene_12259) were a gift from Didier Trono. Media was changed after 8 h; after 52 additional h, media was harvested and passed through 0.45 µm filter (Advantec, catalog #: 25CS045AS) to collect the lentivirus. Furthermore, the lentivirus were concentrated using Lenti-X concentrator (Takara Bio, Catalog #: 631231) and quantified with the qPCR lentivirus titration kit (Abmgood, catalog #: LV900) according to the manufacturer’s instruction, and saved to −80°C for neuron cells transduction.
Sprague Dawley rat E18 brain cortex tissues were obtained from BrainBits, with provided Hibernate EB (HEB) and NbActiv1 media (Springfield, IL). Prior to plating cells, 10-cm dishes or coverslips (Fisher, catalog #: 12-545-80 CIR-1) in a 24-well plate were coated with 4 mL per plate or 500 μL per well of 50 μg/mL poly-D-lysine (PDL, Sigma, catalog #: P6407) at 4°C overnight. The next day PDL was removed and the plates were washed with sterile distilled water two times. Then they were coated with the same volumes of 5 μg/mL Laminin (Sigma, catalog #: L2020) overnight at 4°C. The plates were then put into a 37°C cell incubator while preparing the neurons for 1 h and Laminin was removed immediately before plating neurons.

Neurons were extracted according to instructions from BrainBits. Briefly, connective tissues of cortex were digested with 2 mL of 2 mg/mL of papain (Brain Bits, catalog #: PAP/HE-Ca) at 30°C water bath for 15 min, gently swirling every 5 min. Papain was then removed without disturbing the tissue at the bottom of the tube. The HEB media was then added to the tissue tube. The salinized Pasteur pipette was then used to triturate 30 times very slowly and carefully to not add air bubbles with the tip in the middle of the tube. The undispersed pieces were allowed to settle for one minute. The supernatant with dispersed cells were then transferred to a sterile 15 mL tube. This was spun down at 200 × g for one minute and the supernatant was discarded. Afterwards 1-2 mL of NbActiv1 was added while carefully avoiding air bubbles. Neurons were plated at 1 million per 10-cm dish or 25,000 per well of 24-well plate. The neuronal culture media contained the following: 100 mL Neurobasal A (Gibco, catalog #: 21103049), 2 mL B27 (Gibco, catalog #: 15740440), 0.25 mL GlutaMAX (Gibco, catalog #: 35050061) and 1 mL Penicillin-Streptomycin (HyClone, catalog #: sv30010). Additionally, cytosine β-D-arabinofuranoside hydrochloride (Ara-C hydrochloride) (Sigma, catalog #: C6645) was added from day-in-vitro (DIV) 3 at a final concentration of 2 μM each time as half of the media was changed every three days. At DIV 6, lentivirus transduction was carried out to the neurons as indicated; the multiplicity-of-infection (MOI) was at 10, that is, the ratio of lentivirus count to neuron cells count in each well. At DIV 12, neurons were subjected to protein extraction for co-IP or immunofluorescence staining for confocal microscopy.

Mouse brain homogenization

C57BL/6J mice (Jackson laboratory) at 8–10 weeks were sacrificed, and the cortex was isolated and stored at −80°C. On the day of experiments, the cortex was thawed on ice and homogenized in homogenization buffer (25mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS supplemented with Roche complete protease inhibitor cocktail) using a plastic micro tissue homogenizer, and then sheared by passing 10 times through a 21G needle. Homogenates were centrifuged at 800 g for 10 min at 4°C and supernatants were collected. The pellet was re-homogenized in additional homogenization buffer and centrifuged at 800 × g for 10 min at 4°C, and the supernatant was collected again. The supernatants were combined and rotated at 4°C for 2 h, and then centrifuged at 18,000 × g for 30 min at 4°C. The resulting supernatant was collected as mouse brain homogenate, and its protein concentration was determined by a MicroBCA assay. The animal studies followed the guidelines of the Institutional Animal Care and Use Committees (IACUC) at Case Western Reserve University.

Confocal immunofluorescence

To label cell surface GABA_A receptors, primary neurons that were cultured on coverslips, were fixed with 2% paraformaldehyde in DPBS, blocked with goat serum for 0.5 h at room temperature, and labeled with 100 μL of appropriate anti-α1 (Synaptic Systems, catalog #: 224203), β2/3 (Millipore, catalog #: 05-474), or y2 (Synaptic Systems, catalog #: 224003) antibodies (1:200) for 1 h without detergent permeabilization. Afterwards, they were incubated at room temperature with 500 μL (1:400) of Alexa 594-conjugated goat anti-rabbit antibody (ThermoFisher, catalog #: A11037), or Alexa 594-conjugated goat anti-mouse antibody (ThermoFisher, catalog #: A11032) for 1 h. Afterwards, cells were permeabilized with saponin (0.2%) for 5 min and incubated with DAPI (1 μg/mL) for 3 min to stain the nucleus. The coverslips were then mounted and sealed. For confocal immunofluorescence microscopy, an Olympus IX-81 Fluoview FV1000 confocal laser scanning system was used. A 60X objective was used to collect images using FV10-ASW software. Quantification of the fluorescence intensity was achieved using the ImageJ software from the NIH.

Biotinylation of cell surface proteins

To perform biotinylation assay, 6-cm dishes were coated in a 300-fold dilution of poly-L-lysine (Fisher, catalog #: ICN15017710) at 2 mL per plate for one hour at 37°C. Plates were rinsed twice with DPBS and allowed to air dry. The cells were plated on the coated dishes and incubated for 48 h post-transfection.
The intact cells were washed one time with ice-cold DPBS and incubated with the membrane impermeable biotinylation reagent Sulfo-NHS SS-Biotin (0.5 mg/mL; APEXBio, catalog #: A8005) in PBS containing 0.1 mM CaCl₂ and 1 mM MgCl₂ (PBS+ CM) for 30 min at 4°C to label surface membrane proteins. In order to quench the reaction, the cells were incubated with 1.5 mL of 50 mM glycine in ice-cold DPBS-CM twice for 5 min at 4°C. They were then washed twice with DPBS. The sulfhydryl groups were then blocked by incubating the cells with 5 nM N-ethylmaleimide (NEM) in DPBS-CM for 15 min at room temperature and then the liquid was removed. Cells were resuspended in plates and solubilized overnight at 4°C in lysis buffer (Tris–HCl, 50 mM; NaCl, 150 mM; pH 7.5, 2 mM DDM) supplemented with Roche complete protease inhibitor cocktail and 5 mM NEM. The next day the lysates were centrifuged at 16,000 × g for 10 min at 4°C to pellet cellular debris. The supernatant was saved, and the protein concentration was measured with a MicroBCA assay. Biotinylated surface proteins were affinity-purified from the above supernatant by incubating for 2h at 4°C with 50 μL of immobilized neutravidin-conjugated agarose bead slurry (Fisher, catalog #: PI29200). The samples were then subjected to centrifugation (5,000 × g, 3 min). The beads were washed three times with buffer (Triton X-100, 1%; Tris–HCl, 50 mM; NaCl, 150 mM; pH 7.5) and three times further without Triton X-100. Surface proteins were eluted from beads by incubating for 30 min at room temperature with 80 μL of LSB/ Urea buffer (2x Laemmli sample buffer (LSB) with 100 mM DTT and 6 M Urea, pH 6.8) for SDS-PAGE and Western blotting analysis.

**Cycloheximide-chase assay**
Cycloheximide-chase assay to evaluate protein degradation in cells was carried out according to published procedures (Di et al., 2016). Briefly, cycloheximide (100 μg/mL), a potent protein synthesis inhibitor, was added to cell culture medium. HEK293T cells were then chased for the indicated time and harvested, and total proteins were extracted and subjected to SDS-PAGE and Western blot analysis.

**Endoglycosidase H (endo H) enzyme digestion assay**
To remove asparaginyl-N-acetyl-D-glucosamine in the N-linked glycans incorporated on the α subunit in the ER, total cell lysates were digested with Endo H enzyme (NEBiolab, catalog #: P0703L) with G5 reaction buffer at 37°C for 1h. The Peptide-N-Glycosidase F (PNGase F) enzyme (NEBiolab, catalog #: P0704L) treated samples served as a control for unglycosylated α subunits. Treated samples were then subjected to Western blot analysis.

**Automated patch-clamping with IonFlux Mercury 16 instrument**
Whole-cell currents were recorded 48 h post transfection of GT1-7 or HEK293T cells. Automated patch clamping was performed on the Ionflux Mercury 16 instrument (Fluxion Biosciences, California). The extracellular solution (ECS) contained the following: 142 mM NaCl, 8 mM KCl (Sigma, catalog #: P9541), 6 mM MgCl₂ (Sigma, catalog #: M0250), 1 mM CaCl₂ (Sigma, catalog #: C3306), 10 mM glucose (Sigma, catalog #: G8270), 10 mM HEPES (Sigma, catalog #: H3375). The intracellular solution (ICS) contained the following: 153 mM KCl (Sigma, catalog #: P9541), 1 mM MgCl₂ (Sigma, catalog #: M0250), 5 mM EGTA (Sigma, catalog #: E3889), 10 mM HEPES (Sigma, catalog #: H3375). Briefly, cells were grown to 50 to 70 percent confluence on 10-cm dishes. Then 3 mL Accutase (Sigma Aldrich, catalog #: A6964-500mL) was added and the cells were incubated for 3 min at 37°C until the cells were floating as observed under microscope with minimal clumps. We then pelleted cells with centrifugation for 1 min at 200 × g, removed supernatant and resuspended cells in serum free medium HEK293 SFM II (Gibco, catalog #: 11686-029), supplemented with 25 mM HEPES (Gibco, catalog #: 15630-080) and 1% penicillin streptomycin (Hyclone, catalog #: sv30010). Cells were put on gentle shaking at room temperature for 0.5 to 1 h. Mercury 16 plates were prepared according to manufacturer suggestions. Whole-cell GABA-induced currents were recorded at a holding potential of −60 mV, at 100 μM or 1 mM GABA concentration as indicated. The signals were acquired and analyzed by Fluxion Data Analyzer.

**QUANTIFICATION AND STATISTICAL ANALYSIS**
All data are presented as mean ± SEM. Statistical significance was evaluated using Student's t-test if two groups were compared and one-way ANOVA followed by post-hoc Tukey test if more than two groups were compared. A p< 0.05 was considered statistically significant. *, p< 0.05; **, p< 0.01.